We have constructeda computermodel,basedon experimentaldata and the known properties of the enzymes involved, of the aspartate aminotransferase and alanine aminotransferase assays by the coupled-enzyme procedure of Henry et al. [Amer. J. Clln. Pathol. 34, 381 (1960) izing that assay. In this study we present a method for using mathematical representations of enzyme kinetics as models for enzyme assays. These models are combined with a standard computer optimization procedure to fully utilize the computer as a tool in assay design.
34, 381 (1960) ] to assay sera from normal persons and persons with liver disease or myocardial infarct. Observed inhibitions of aminotransferase activity were included in the models. When the computer models are combined with art optimizationprocedure, substrate concentrations that result in maximum enzyme activity for individual sera are obtained. Aminotransferase activity is not much affected by rather large changes in these concentrationsaround the optimum. The optimal concentrations we computed are close to those currently accepted. The computer methods involved may be applied to other assays, and factors other than reagent concentration may be optimized.
In recent years, workers in clinical enzymology have given considerable attention #{149}to determining the optimal conditions for various assays (1) (2) (3) (4) In this case, we selected non-unique sets of rate constants of the right order of magnitude, which yield the observed kinetic constants.
The more realistically a model describes the actual biochemistry of a system, the more information can be obtained from it (9). For the optimization process, however, the models are functional in nature, and the overriding concern is that the model accurately simulate the laboratory assay over the range of conditions that would be encountered.
We combined the computer model described above with an optimization procedure developed by Fletcher and Powell (8 
Results and Discussion
Our experimental data are summarized in Table 1 . Figures 3 and 4 show representative fits of our model to the experimental data for two sera. As shown by the summary in Table 2 , the data for alanine aminotransferase exhibited a greater degree of competitive inhibition than that for aspartate aminotransferase. Also, the data for both enzymes show much greater substrate inhibition for a-ketoglutarate than for the amino acid substrate.
We could not find a consistent set of rate constants that would produce the desired degree of substrate inhibition in all sera. Therefore, the substrate inhibition was linked to the presence of an uncompetitive inhibitor, and the concentration of this inhibitor was adjusted to appropriately decrease activity at high substrate concentration. The presence of a noncompetitive inhibitor of aminotransferase in serum would be detectable by a failure to account for all the activity of a sample of punfled enzyme added to that serum. Such experiments were performed for both aminotransferases. For ala- the optimization program would show that the measured enzyme activity of 72 Karmen units for one of the sera of our study could be increased to 176 Karmen units by increasing the alanine to 915 mmol/liter and the a-ketoglutarate to 19 mmol/liter.
For enzymes that have been studied as intensively as these two aminotransferases, the finding that the computed optimal conditions agree with those determined empirically is sufficient to confirm the validity of the optimization method. In both cases, the enzyme kinetics have been studied thoroughly and all kinetic constants carefully derived from statistical analysis of experimental data (10, 11 ). For enzymes that are less well characterized, the methods described here must be applied with caution, because a model is only as reliable as the data on which it is based. In such cases, there should be sufficient kinetic data to define the mechanism, and optimal conditions should be verified experimentally.
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